title: [New results in the management of hypercholesterolemia].
abstract: Cardiovascular disease is a major cause of morbidity and mortality worldwide. During the last decade huge amount of laboratory and clinical evidence proved link between serum lipid concentration and the development of coronary heart disease. The Adult Treatment Panel III of the National Cholesterol Education Program issued an evidence-based set of guidelines on cholesterol management. Since the publication of these guidelines numbers of new clinical trials and experimental results have been published. Recently completed clinical trials have indicated that reduction of low-density lipoprotein cholesterol to goals lower than the previously considered appropriate 2,6 mmol/l, produce further cardiovascular risk reduction in high risk individuals. There is growing evidence of the role of inflammation in the development of atherosclerosis and cardiovascular disease. Numerous studies have demonstrated that elevated C-reactive protein may be an independent cardiovascular risk factor. Statin therapy has produced a greater cardiovascular risk reduction in those patients whose C-reactive protein level was high. Ezetimibe is a new intestinal cholesterol uptake inhibitor, which reduces LDL cholesterol in monotherapy or in combination with statins. Lately a variety of new antilipemic agents are being developed. The present review summarizes some of these new results and their effect on cholesterol lowering therapy.
authors.affiliation: Semmelweis Egyetem, Altalános Orvostudományi Kar, II. Belgyógyászati Klinika, Budapest. sarbea@bel2.sote.hu
authors.forename: Beatrix
authors.initials: B
authors.lastname: Sármán
mesh_terms: D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D001384:Azetidines / Q000627:therapeutic use; D002097:C-Reactive Protein / Q000378:metabolism; D002352:Carrier Proteins / Q000037:antagonists & inhibitors; D053480:Cholesterol Ester Transfer Proteins; D008078:Cholesterol, LDL / Q000097:blood*; D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000209:etiology / Q000517:prevention & control*; D004359:Drug Therapy, Combination; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D019317:Evidence-Based Medicine; D000069438:Ezetimibe; D006023:Glycoproteins / Q000037:antagonists & inhibitors; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D006937:Hypercholesterolemia / Q000097:blood / Q000150:complications / Q000188:drug therapy / Q000628:therapy; D007249:Inflammation; D017410:Practice Guidelines as Topic; D002785:Sterol O-Acyltransferase / Q000037:antagonists & inhibitors
chemical_list: D000924:Anticholesteremic Agents; D001384:Azetidines; C506642:CETP protein, human; D002352:Carrier Proteins; D053480:Cholesterol Ester Transfer Proteins; D008078:Cholesterol, LDL; D004791:Enzyme Inhibitors; D006023:Glycoproteins; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D002097:C-Reactive Protein; D002785:Sterol O-Acyltransferase; C493492:sterol O-acyltransferase 1; D000069438:Ezetimibe